Introduction
Transcatheter aortic valve implantation (TAVI) has become an established therapy for severe, symptomatic aortic valve stenosis in inoperable patients 1, 2 and in high surgical risk patients. [3] [4] [5] [6] The new joint European Society of Cardiology (ESC)/European Association of Cardio-Thoracic Surgery (EACTS) Guidelines (2017) for the management of valvular heart disease contain indications that have been further expanded to intermediate-risk patients based on various clinical parameters such as age, previous cardiac surgery, and anatomical considerations, if consented by an interdisciplinary heart team. 7 This is supported by randomized clinical trials (RCTs) analysing the outcomes of intermediate-risk patients. 8, 9 Presently, some limited data indicate non-inferiority of TAVI vs. surgical aortic valve replacement (SAVR) in low-risk patients. 10 However, according to present guidelines, low surgical risk patients should primarily undergo SAVR.
With advanced experience, specific patient selection, improved TAVI technology, and further ongoing RCTs addressing the low surgical risk cohort (NOTION 2; PARTNER 3; EVOLUT low risk), it is becoming increasingly important to gain outcome data in patients undergoing TAVI who are formally at low surgical risk. Large registries that collect data from both SAVR and TAVI patients can be useful to gain further knowledge. In contrast to the highly selected populations of RCTs, large registries have the advantage that they reflect real-world populations, and should therefore, be used as an important additional tool.
Thus, the aim of this study was to analyse in-hospital, short-term, and 1 year outcome data from the German Aortic Valve Registry (GARY) in patients undergoing isolated TAVI or SAVR in the years 2014 and 2015.
Methods

Registry design
Initiated in 2010, the GARY is the largest, prospective, multicentre registry that monitors the safety and efficacy of interventional and surgical aortic valve procedures in Germany. It is an all-comers registry with voluntary patient participation. A centralized follow-up database collects data for 30 days and 1, 3, and 5 years after the index aortic valve procedure. The registry design has been described in detail previously. 11 In brief, data from 78 hospitals performing aortic valve interventions and/or surgical aortic valve replacement were collected using standardized case report forms to record demographic, clinical, procedural, and follow-up data. The present analysis is focused on data of patients who were treated in 2014 and 2015. In-hospital data (upon discharge or death), 30-day data, and 1-year follow-up data were analysed. The investigators had full access to the data and control of the analysis. Initial approval for GARY was obtained from the Freiburg International Ethical Committee, and patients gave written informed consent before the procedure.
Patient population
In Adjusted and unadjusted comparison of the SAVR and TAVI patients for in-hospital, 30-day, and 1 year mortality were performed with the Cox proportional hazard model. Since SAVR and TAVI were not randomly assigned to patients, a weighted propensity score model was used to adjust the Cox regression and the comparison of the baseline characteristics. Variables included in the propensity score model were age, sex, BMI, New York Heart Association class, coronary artery disease (CAD), previous myocardial infarction, previous PCI, previous cardiac surgery, chronic obstructive pulmonary disease, pulmonary hypertension, diabetes mellitus, creatinine >2 mmol/L, chronic dialysis, atrial fibrillation, left ventricular ejection fraction, mitral regurgitation > _2
, tricuspid regurgitation > _2
, peripheral vascular disease, and previous pacemaker or implantable cardioverter-defibrillator implantation.
In this model, patients receiving SAVR were weighted in a way that these variables are approximately comparable. For example, the younger age of the SAVR patients led to a higher weight of the older patients in the SAVR group.
In general, a propensity score model was built to define a single propensity score from all these variables which defines the weights of the patients in the SAVR group.
Confidence intervals of survival rates for unadjusted analysis were calculated using a log-log approach. Confidence intervals of survival rates for adjusted analysis were calculated using a basic bootstrap approach with 2500 replicates.
A two-sided P-value of < _0.05 was considered statistically significant. Statistical analysis was performed with SAS statistical software (version 9.4, SAS Institute, Cary, NC, USA) and R (R Foundation for Statistical Computing, Vienna, Austria). The R packages 'twang' and 'survey' were used for calculating propensity score weights and the corresponding weighted analysis. 12 The study endpoint was in-hospital, 30-day, and 1-year survival.
Results
Patient characteristics
After excluding all patients with an STS score > _4%, simultaneous SAVR with CABG, simultaneous TAVI with PCI, patients with
endocarditis, double data entries, and missing relevant clinical data, a total of 20 549 patients remained for further analysis. As expected for low surgical risk patients, the majority of patients underwent SAVR (14 487) rather than TAVI (6062). Despite the cut-off of an STS score <4%, characteristics differed significantly. Most relevantly, TAVI patients were older (TAVI vs. SAVR: 78.9 ± 5.6 vs. 67.5 ± 10.8; P < 0.0001), had a higher STS score (TAVI vs. SAVR: 2.9 ± 0.7 vs. 1.8 ± 0.9; P < 0.0001), a higher logistic EuroSCORE (TAVI vs. SAVR: 12.9 ± 8.3 vs. 5.9 ± 4.7; P < 0.0001), more often previous cardiac surgery (TAVI vs. SAVR: 13% vs. 5.8%; P < 0.0001), and more often pulmonary hypertension (TAVI vs. SAVR: 10.7% vs. 3 .7%; P < 0.0001). Since all patients in the TAVI group were subjected to a heart team decision, some of these baseline characteristics partly explain the reason for performing TAVI in patients with an STS score of less than 4%. In 2014 and 2015, the logistic EuroSCORE was the primary method of risk calculation that was used in Germany to justify reimbursement for TAVI procedures, requiring a logistic EuroSCORE of > _20%. Calculation of EuroSCORE and STS score differ significantly; thus, some patients may have a logistic EuroSCORE > _20% and at the same time a STS score of <4%. A total of 888 out of the 6062 TAVI patients (14.6%) had a EuroSCORE of > _20%. Also, 444 patients (7%) were classified as having porcelain aorta, justifying TAVI independent of a risk score. Additional reasons that were documented for choosing TAVI were malignant tumours in 162 patients (2.7%) and frailty in 2974 patients (49.1%). Frailty was defined in a semi-quantitative way when three out of five criteria were fulfilled: >10% weight-loss within 1 year, reduced muscle strength, self-reported exhaustion, slowness (>6 s for 5 m walking), reduced physical activity. 
Procedural data
The majority of TAVIs were performed as TV TAVI (84.3%) with a lower percentage of TA TAVI (15.7%). Of TV TAVIs, the vast majority was transfemoral (5043/5113, 98.6%) while only 32/5113 (0.6%) were transaortic, 27/5113 (0.5%) were transaxillary, and 11/5133 (0.2%) were other access routes, such as carotid. Thus, TV can be regarded as mainly transfemoral and alternative routes will have no impact on data analysis. Fifty-eight percent of all TAVIs were performed under general anaesthesia, with 72% using rapid pacing during implantation. 0.6% needed conversion to surgery and 0.5% showed pericardial tamponade. Vascular complications were observed in 2.2% of TAVI patients. Post-implantation mean aortic valve gradients were lower and aortic regurgitation grades higher in TAVI than in SAVR patients. New permanent pacemaker implantation rates after the procedure were higher in the TAVI group (TAVI vs. SAVR: 15.1% vs. 4 .4%; P < 0.0001). Supplementary material online, In-hospital, 30-day, and 1 year survival
The major endpoint of this study was survival. Since the TAVI group was older and had a higher incidence of co-morbidities, an adjusted comparison of the SAVR and TAVI patients was applied in order to compare outcome data (unadjusted data are shown in Table 2A ). Inhospital survival was documented upon discharge or death by the index hospital. The weighted analysis showed a higher survival rate for TAVI patients than for SAVR patients (survival TAVI vs. SAVR:
98.5% vs. 97.3%; P = 0.003). Thirty-day and 1 year survival rates were documented by the centralized follow-up assessment that was performed after 1 year. Survival rates after 30 days were similar to those for in-hospital data (survival TAVI vs. SAVR: 98.1% vs. 97.1%; P = 0.014). At 1 year, survival rates did not differ significantly (survival TAVI vs. SAVR: 90.0% vs. 91.2%; P = 0.158) (Figure 3) . It is well known that patients who undergo TA TAVI tend to have more co-morbidities and thus have lower survival rates than patients who are eligible for TV TAVI. Therefore, a separate analysis was carried out that compared either TV TAVI or TA TAVI patients with the SAVR group.
For TV TAVI patients, the weighted analysis showed a significantly higher in-hospital survival than for SAVR patients (survival TV TAVI Table 2B) . Thirty-day survival rates were similar to in-hospital rates (survival TV TAVI vs. SAVR: 98.3% vs. 97.0%; P = 0.002). At 1 year, survival rates did not differ significantly (survival TV TAVI vs. SAVR: 90.4% vs. 91.2%; P = 0.368). Figure 3 and Table 2C show survival data for comparison of TV TAVI and SAVR patients. For TA TAVI patients weighted analysis showed no significant difference in in-hospital survival compared with SAVR patients (survival TA TAVI vs. SAVR: 96.9% vs. 97.2%; P = 0.780). Thirty-day survival rates were similar to in-hospital survival rates (survival TA TAVI vs. SAVR: 96.9% vs. 96.8%; P = 0.914). At 1 year, survival was lower in the TA TAVI group (survival TA TAVI vs. SAVR: 87.6% vs. 90.9%; P = 0.042). Figure 4 and Table 2D show survival data for comparison of TA TAVI and SAVR patients.
Discussion
This is the first large registry analysis of patients with an STS score <4%, receiving isolated TAVI or SAVR.
In patients defined as having low surgical risk (STS score <4%), SAVR is recommended. Nevertheless, some of these patients still qualify for TAVI due to specific co-morbidities. Increasingly, we are seeing more patients who object to surgery, centres that are more liberal in issuing an indication for TAVI as well as first study data that include patients with an STS score <4%. 8, 10 Thus, a relevant number of patients is already being treated with TAVI despite an STS score <4%. Therefore, TAVI outcome data in patients with an STS score <4% will become a major focus of research in the coming years. Without any doubt, randomized controlled trials will have the largest impact on comparing TAVI and SAVR in this group. However, large registries such as GARY can contribute important information on TAVI performance before sufficient randomized data are available. In addition, large registries benefit from larger patient numbers and real-world patient recruitment, in contrast to the lower numbers of highly selected patients in RCTs.
In this study, we analysed the two most recent years in GARY with a completed 1-year follow-up (2014 and 2015). It is not surprising that the TAVI population was older and had more relevant comorbidities than the SAVR population.
The significant differences in these two populations, especially the great difference in age, do not allow a direct comparison of the two groups. An ideal propensity score model was chosen to reduce bias. In our analysis, we used the propensity score-weighting model with the advantage of lower mean squared error compared with matching methods. 13 In addition, a matched pair analysis would have resulted in very few patients for each group. The major endpoint of this study was in-hospital, 30-day, and 1-year survival. With the propensity score-weighting model, SAVR patients were weighted in way that important baseline variables were more comparable between the groups. Using this approach, TAVI showed significantly higher in-hospital and 30-day survival compared with SAVR overall. At 1 year, no significant difference was seen between the two groups. Considering the limited amount of data presently available in low-risk patients undergoing TAVI, these results are in accordance with the few RCT results available and suggest non-inferiority of TAVI compared with SAVR even in lower-risk patients.
An additional, separate analysis was performed for TV and TA TAVI patients. The results for TV TAVI patients were similar to those of the total TAVI population. On the other hand, TA TAVI patients showed non-inferiority in the short-term follow-up but inferiority to SAVR patients in the 1-year follow-up. This is not surprising, since these patients are well known to have more co-morbidities than TV TAVI patients. The rather small number of TA patients in this cohort further limits interpretation of TA data.
This study is limited by its non-randomized design, being a large, prospective, and all-comers registry. This leads to significant differences in the two patient groups that prohibit a direct comparison and necessitate a propensity score-weighting model to be able to compare data. However, as mentioned above, this registry has the advantage of permitting large-scale data analysis and real world, all-comers data collection. The selection algorithm used to exclude patients poses another limitation. We chose patients with isolated TAVI and isolated SAVR, but no patients with combined CABG and SAVR or PCI and TAVI. Transcatheter aortic valve implantation patients with relevant CAD mostly receive isolated TAVI with either staged PCI or even conservative treatment of coronary arteries, whereas SAVR patients with relevant CAD mostly receive SAVR with CABG. This may favour data for SAVR patients in this analysis. Another limitation is based on the rapid development of TAVI technology. Data were obtained with TAVI techniques used during the years 2014 and 2015; thus, further analyses will be necessary in the coming years to address new technical achievements. Finally, as GARY is limited by its voluntary participation of patients, data acquisition from all patients who were treated in 2014 and 2015 is not possible. However, it is unlikely that this lack of completeness would change data quality in a relevant way, since patients without written informed consent should be present in both groups and all risk score categories.
Conclusion
In conclusion, this is the first large-scale registry analysis comparing TAVI patients with SAVR patients in a low surgical risk cohort. In a propensity score-weighted model, TAVI patients had higher survival rates than SAVR patients in a short-term follow-up. After 1 year, there was no difference in survival between the two groups. These findings will be an important aspect in the interpretation of TAVI data in low-risk patients, as they suggest non-inferiority for TAVI compared with surgery (up to 1 year). Future data on randomized controlled trials that explicitly recruit low-risk patients will help to further understand feasibility and long-term performance of TAVI in low surgical risk patients.
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